About us
Mission and values
Corporate responsibility
History
Investors Relations
Products & Services
Efficacy / Models
General Toxicology
Safety Pharmacology / Telemetry
Genetic Toxicology
Reproduction & Fertility
Carcinogenicity
Ecotoxicology
Specializations
Drug Metabolism and Pharmacokinetcs
Bio/Analytical Chemistry
Biological Control / Potency Tests
Derek
REACH
Support
Animal Welfare
Events
Trade shows
Corporate Events
Career
Career Opportunities
Career Management & Training
Employee Benefits
Visit our main locations
Canada
/
Denmark
/
Hungary
Events
Seminar: How to Screen for Arrhythmias in Safety Pharmacology...
SOT 2010, Booth # 601
More trade shows
More corporate events
Fact Sheet
Q3 2009 Highlights
Revenue
of $13.1 million
Net loss
of $1.7 million
Net loss per share
of $0.09
Backlog
of $28.1 million
Active backlog
of $11.5 million
Investor Information
TSX Symbol:
LRI
Shares Outstanding: 52.7M
Fully Diluted: 58.2M
Market Cap. Nov. 16, 09: $25.3 M.
Year-end: December 31st
Ownership
Management: 1%
Institutions: ≈ 75%
Retail: ≈ 24%
Management Team
Luc Mainville, President and CEO
Louise Bussières, Vice-President, Finance
Andy Makin, Managing Director, Denmark
Christopher Banks, Managing Director, Hungary
Denis Pilon, Chief Operating Officer, Canada
2009 Highlights
$39.9million revenue
$4.3 million net loss
$0.24 loss per share
Newsletter
Latest information on
LAB Research
Customer service
1-888-353-2240
Document center
Inquiry form
Client center
Terms of Use
|
Contact
|
Site Map
Top of page
Français
|
Home
|
About
|
Investor Relations
|
Careers
|
Corporate Profile
|
Products
|
Animal Welfare
|
Events
|
Customers Services
Copyright © 2006 LAB Research Inc. All Rights Reserved |
Data Privacy Policy